181 related articles for article (PubMed ID: 36045586)
1. FOXP3 expression diversifies the metabolic capacity and enhances the efficacy of CD8 T cells in adoptive immunotherapy of melanoma.
Conde E; Casares N; Mancheño U; Elizalde E; Vercher E; Capozzi R; Santamaria E; Rodriguez-Madoz JR; Prosper F; Lasarte JJ; Lozano T; Hervas-Stubbs S
Mol Ther; 2023 Jan; 31(1):48-65. PubMed ID: 36045586
[TBL] [Abstract][Full Text] [Related]
2. TCR-induced FOXP3 expression by CD8
Lozano T; Conde E; Martín-Otal C; Navarro F; Lasarte-Cia A; Nasrallah R; Alignani D; Gorraiz M; Sarobe P; Romero JP; Vilas A; Roychoudhuri R; Hervás-Stubbs S; Casares N; Lasarte JJ
Cancer Lett; 2022 Mar; 528():45-58. PubMed ID: 34973390
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function.
Sukumar M; Liu J; Ji Y; Subramanian M; Crompton JG; Yu Z; Roychoudhuri R; Palmer DC; Muranski P; Karoly ED; Mohney RP; Klebanoff CA; Lal A; Finkel T; Restifo NP; Gattinoni L
J Clin Invest; 2013 Oct; 123(10):4479-88. PubMed ID: 24091329
[TBL] [Abstract][Full Text] [Related]
4. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
5. Enhancing CD8
Zhang Y; Kurupati R; Liu L; Zhou XY; Zhang G; Hudaihed A; Filisio F; Giles-Davis W; Xu X; Karakousis GC; Schuchter LM; Xu W; Amaravadi R; Xiao M; Sadek N; Krepler C; Herlyn M; Freeman GJ; Rabinowitz JD; Ertl HCJ
Cancer Cell; 2017 Sep; 32(3):377-391.e9. PubMed ID: 28898698
[TBL] [Abstract][Full Text] [Related]
6. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
[TBL] [Abstract][Full Text] [Related]
7. CD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response.
Le DT; Ladle BH; Lee T; Weiss V; Yao X; Leubner A; Armstrong TD; Jaffee EM
Int J Cancer; 2011 Aug; 129(3):636-47. PubMed ID: 20857491
[TBL] [Abstract][Full Text] [Related]
8. Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.
Anichini A; Molla A; Vegetti C; Bersani I; Zappasodi R; Arienti F; Ravagnani F; Maurichi A; Patuzzo R; Santinami M; Pircher H; Di Nicola M; Mortarini R
Cancer Res; 2010 Nov; 70(21):8378-87. PubMed ID: 20861189
[TBL] [Abstract][Full Text] [Related]
9. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3
Sharma A; Subudhi SK; Blando J; Scutti J; Vence L; Wargo J; Allison JP; Ribas A; Sharma P
Clin Cancer Res; 2019 Feb; 25(4):1233-1238. PubMed ID: 30054281
[TBL] [Abstract][Full Text] [Related]
10. Providence of the CD25
Chakraborty S; Bhattacharjee P; Panda AK; Kajal K; Bose S; Sa G
Immunol Cell Biol; 2018 Nov; 96(10):1035-1048. PubMed ID: 29768737
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
[TBL] [Abstract][Full Text] [Related]
12. Co-transfer of tumor-specific effector and memory CD8+ T cells enhances the efficacy of adoptive melanoma immunotherapy in a mouse model.
Contreras A; Beems MV; Tatar AJ; Sen S; Srinand P; Suresh M; Luther TK; Cho CS
J Immunother Cancer; 2018 May; 6(1):41. PubMed ID: 29843822
[TBL] [Abstract][Full Text] [Related]
13. Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8
Gemta LF; Siska PJ; Nelson ME; Gao X; Liu X; Locasale JW; Yagita H; Slingluff CL; Hoehn KL; Rathmell JC; Bullock TNJ
Sci Immunol; 2019 Jan; 4(31):. PubMed ID: 30683669
[TBL] [Abstract][Full Text] [Related]
14. T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3.
Quatromoni JG; Morris LF; Donahue TR; Wang Y; McBride W; Chatila T; Economou JS
J Hematol Oncol; 2011 Nov; 4():48. PubMed ID: 22112546
[TBL] [Abstract][Full Text] [Related]
15. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
16. Absence of amplification of CD4+CD25(high) regulatory T cells during in vitro expansion of tumor-infiltrating lymphocytes in melanoma patients.
Knol AC; Lemaître F; Pandolfino MC; Volteau C; Quéreux G; Saiagh S; Khammari A; Viguier M; Dréno B
Exp Dermatol; 2008 May; 17(5):436-45. PubMed ID: 18312383
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.
Spranger S; Spaapen RM; Zha Y; Williams J; Meng Y; Ha TT; Gajewski TF
Sci Transl Med; 2013 Aug; 5(200):200ra116. PubMed ID: 23986400
[TBL] [Abstract][Full Text] [Related]
18. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors.
Nair RE; Kilinc MO; Jones SA; Egilmez NK
J Immunol; 2006 Jun; 176(12):7325-34. PubMed ID: 16751376
[TBL] [Abstract][Full Text] [Related]
19. Reinforce the antitumor activity of CD8
Nabe S; Yamada T; Suzuki J; Toriyama K; Yasuoka T; Kuwahara M; Shiraishi A; Takenaka K; Yasukawa M; Yamashita M
Cancer Sci; 2018 Dec; 109(12):3737-3750. PubMed ID: 30302856
[TBL] [Abstract][Full Text] [Related]
20. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
